JYP0061 + glucocorticoids

**JYP0061 + glucocorticoids** is a combination therapy under investigation primarily for autoimmune and neuroinflammatory diseases, notably acute neuromyelitis optica spectrum disorder (NMOSD) and atopic dermatitis. JYP0061 is an orally administered small molecule developed by Guangzhou Jiayue Pharmaceutical Technology, with ongoing phase 2 trials evaluating its efficacy when combined with glucocorticoids (given orally and intravenously) compared to monotherapy or other regimens. The precise mechanism of JYP0061 is not published, though it is studied as a potential immunomodulator for autoimmune indications. Glucocorticoids are well-established steroid hormones that act through binding cytosolic glucocorticoid receptors, exerting anti-inflammatory and immunosuppressive effects. The combination is designed to provide synergistic immunosuppression, with JYP0061 potentially reducing required steroid dosages[1][3][5][7].